Fluvoxamine Administration in Moderate SARS-CoV-2 (COVID-19) Infected Patients
Status:
Recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
This is a randomized, double-blind, placebo-controlled, adaptive two-stage design, human
phase 2 study, with add-on treatment arrangement of fluvoxamine or placebo on top of standard
of care (base therapy: the actual proposed therapy of moderate SARS-CoV-2 infected patients
according to "Hungarian Coronavirus Handbook", including antiviral and immunmodulant therapy
and reconvalescent plasma therapy in serious cases as indicated by the investigator).